Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluating the efficacy and safety of radiotherapy combined with Tislelizumab, Liposomal Irinotecan, and Capecitabine in patients with locally advanced mid-lower rectal cancer with pMMR.. Patients would be included as:1. Aged between 18-75 years, with no gender restrictions; 2. Biopsy pathology confirmed as pMMR type locally advanced mid-lower rectal adenocarcinoma (tumor lower margin ≤ 10 cm from the anal verge); 3.With the following high-risk factors: T3N+/T4/N2/EMVI+/MRF+/lateral lymph node metastasis/inability to preserve anal function during surgery; 4. No distant metastasis observed in routine chest and abdominal CT scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony biopsją zaawansowany rak odbytnicy pMMR
- •Nowotwór znajduje się nie wyżej niż 10 cm od odbytu
- •Obecne czynniki ryzyka wysokiego (zaawansowana zmiana, zajęte węzły chłonne lub ryzyko utraty funkcji zwieracza)
- •Brak przerzutów potwierdzony tomografią klatki piersiowej i brzucha
- •Prawidłowe wyniki badań krwi (liczba białych krwinek, płytek, hemoglobina)
- •Prawidłowa funkcja wątroby i nerek
- •Kobieta w wieku rozrodczym - ujemny test ciąży i zgoda na antykoncepcję na 6 miesięcy po leczeniu
✗ Disqualifies
- •Inne nowotwory złośliwe w ciągu ostatnich 5 lat
- •Aktywna, niekontrolowana infekcja bakteryjna, wirusowa lub grzybicza wymagająca leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Shantou University Medical College Cancer Hospital
Shantou, China
The First Affiliated Hospital of Shantou University Medical College
Shantou, China
Trial contact
Jiarui Lin
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.